非甾体盐皮质激素受体（MR）拮抗剂Finerenone在临床研究中显示出降压作用并改善了心脏功能，但其在预防和治疗高血压性心室重构中的作用及靶点仍不明确。本研究利用高血压大鼠评估了Finerenone对高血压性心室重构和心脏功能的益处，并确定了相关靶点。

Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, ...

Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kidney disease (CKD) with ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that detailed results from the FIDELIO-DKD Phase III study demonstrated that the investigational drug finerenone slowed the progression of ...

Sophia Antipolis, France – 28 Aug 2021: Finerenone reduces the risk of cardiovascular and renal outcomes compared to placebo in patients with type 2 diabetes and all stages of kidney disease. That’s ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adverse outcomes to finerenone did not vary by chronic ...

Please provide your email address to receive an email when new articles are posted on . For adults with mild heart failure, finerenone was not associated with eGFR benefits compared with placebo.

Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced it is further investing in MOONRAKER— its clinical development program to investigate Kerendia ® (finerenone) as a potential treatment for heart ...